Volume 4.22 | Jun 11

Hematopoiesis News 4.22 June 11, 2013
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Matrix-Embedded Osteocytes Regulate Mobilization of Hematopoietic Stem/Progenitor Cells
Researchers demonstrated that osteocytes, the major cellular component of mature bone, are regulators of hematopoietic stem/progenitor cell egress. [Cell Stem Cell] Abstract | Graphical Abstract

A New System for High-Throughput Cell Isolation Directly from Whole Blood
PUBLICATIONS (Ranked by impact factor of the journal)


Hematopoietic Progenitor Cell Lines with Myeloid and Lymphoid Potential
Investigators showed that retroviral delivery of an estrogen-regulated form of Hoxb8 into mouse bone marrow cells can be used along with Flt3 ligand to conditionally immortalize early hematopoietic progenitor cells. [Nat Methods] Abstract

HDAC3 Is Essential for DNA Replication in Hematopoietic Progenitor Cells
Because Histone deacetylase 3 (HDAC3) associates with oncoproteins that drive leukemia and lymphoma, researchers engineered a conditional deletion allele in mice to explore the physiological roles of Hdac3 in hematopoiesis. [J Clin Invest] Full Article | Press Release

Self-Renewal of Single Mouse Hematopoietic Stem Cells Is Reduced by JAK2V617F without Compromising Progenitor Cell Expansion
Human myeloproliferative neoplasms are thought to reflect transformation of a hematopoietic stem cell (HSC) and the majority harbor an acquired V617F mutation in the JAK2 tyrosine kinase, making them a paradigm for studying the early stages of tumor establishment and progression. By using conditional knock-in mice, investigators showed that the HSC defect resulting from expression of heterozygous human JAK2V617F is both quantitative (reduced HSC numbers) and qualitative (lineage biases and reduced self-renewal per HSC). [PLoS Biol] Full Article | Press Release

Runx3 Deficiency Results in Myeloproliferative Disorder in Aged Mice
Investigators showed the hematopoietic phenotypes in Runx3 conditional knockout (KO) mice: while young Runx3 KO mice did not exhibit any significant hematopoietic defects, aged Runx3 KO mice developed a myeloproliferative disorder characterized by myeloid-dominant leukocytosis, splenomegaly and an increase of hematopoietic stem/progenitor cells. [Blood] Abstract

An MLL-Dependent Network Sustains Hematopoiesis
Researchers identified and characterized part of the mixed lineage leukemia (Mll)-dependent transcriptional network in hematopoietic stem cells with an integrated approach by using conditional loss-of-function models, genomewide expression analyses, chromatin immunoprecipitation, and functional rescue assays. [Proc Natl Acad Sci USA] Abstract | Press Release

Myeloid/Microglial Driven Autologous Hematopoietic Stem Cell Gene Therapy Corrects a Neuronopathiclysosomal Disease
The authors demonstrated compelling evidence of neurological disease correction using autologous myeloid driven lentiviral-hematopoietic stem cell gene therapy in mucopolysaccharidosistype IIIA mice. [Mol Ther] Abstract

Organopalladium Compound 7b Targets Mitochondrial Thiols and Induces Caspase-Dependent Apoptosis in Human Myeloid Leukemia Cells
Patented organopalladium compounds derived from the reaction of N,N-dimethyl-1-phenethylamine (dmpa) with [1,2-ethanebis(diphenylphosphine)] (dppe) exhibited a potent antitumor activity in vivo and in vitro in melanoma cells. Researchers showed that the cyclopalladated derivative [Pd2(R(+))C2, N-dmpa)2(μ-dppe)Cl2], named compound 7b, was highly effective to promote cell death in the K562 human leukemia cells and its mechanisms of action were investigated. [Cell Death Dis] Full Article


CMV Reactivation after Allogeneic HCT and Relapse Risk: Evidence for Early Protection in Acute Myeloid Leukemia
The association between CMV reactivation and relapse was evaluated in a large cohort of patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, lymphoma, and myelodysplastic syndrome who underwent allogeneic hematopoietic cell transplantation (HCT). [Blood] Abstract

Outcomes of Allogeneic Hematopoietic Cell Transplant in Patients with Dyskeratosis Congenita
Investigators described outcomes after allogeneic transplantation in 34 patients with dyskeratosis congenita. [Biol Blood Marrow Transplant] Abstract

Outcomes and Costs of Autologous Stem Cell Mobilization with Chemotherapy Plus G-CSF vs G-CSF Alone
Chemotherapy plus G-CSF (C+G) and G-CSF alone are two of the most common methods used to mobilize CD34+ cells for autologous hematopoietic SCT. In order to compare and determine the real-world outcomes and costs of these strategies, scientists performed a retrospective study of 226 consecutive patients at 11 medical centers, of whom 55% of lymphoma patients and 66% of myeloma patients received C+G. [Bone Marrow Transplant] Abstract

NEW STEMvision CB, BM & MPB Algorithms

A Role for DEK in Stem/Progenitor Cell Biology
This review covers the uniqueness of DEK, what is known about how it now functions as a nuclear protein and also as a secreted molecule that can act in paracrine fashion, and how it may be regulated in part by Dipeptidylpeptidase 4, an enzyme known to truncate and modify a number of proteins involved in activities on hematopoietic cells. [Stem Cells] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoietic research field.

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.

BioLineRx Enrolls First Patient in Phase II Clinical Trial for BL-8040, for Treatment of Leukemia
BioLineRx announced enrollment of the first patient in a Phase II trial for BL-8040, for the treatment of acute myeloid leukemia. The patient was enrolled at the MD Anderson Cancer Center in Houston, Texas. [BioLineRx] Press Release

Fujifilm Initiates Phase I Clinical Trial in Japan for the Anticancer Agent “FF-10501” in Patients with Relapsed or Refractory Myelodysplastic Syndromes
FUJIFILM Corporation has initiated Phase I clinical trial for the anticancer agent “FF-10501” in patients with relapsed or refractory myelodysplastic syndromes in Japan. [FUJIFILM Corporation] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW ESH/Eurocord-Ed/Eurocord World Cord Blood Congress IV and Innovative Therapies for Sickle Cell Disease
October 24-27, 2013
Monaco, Monaco

Visit our events page to see a complete list of events in the hematopoietic community.

NEW Postdoctoral Positions – Stem Cell Biology and Epigenetics (University of Wisconsin-Madison)

NEW Director of Cell Processing Facility (S L Collins Associates, Inc.)

PhD Student Position – Hematopoietic Stem Cells (Katholieke Universiteit Leuven)

Research Associate – Stem Cell and Leukemia Epigenetics (King’s College London)

Postdoctoral Fellow – Radiobiology and Hematopoietic Stem Cell Biology (Indiana University School of Medicine)

Postdoctoral Researcher – Hematopoietic Stem Cells (Albert Einstein College of Medicine)

Postdoctoral Fellow – Hematopoietic and Malignant Stem Cells (Istanbul University Institute of Experimental Medicine)

Postdoctoral Fellow – Stem Cells and Cancer (Tsinghua University)

Postdoctoral Fellow – Stem Cell and Cancer Biology (Johns Hopkins University School of Medicine)

Studentship – Novel Mechanisms in Blood Cancers Drug-Resistance (University of East Anglia)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us